T45.692A Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter

Name of the Condition

• Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter (ICD-10 code: T45.692A)

Summary

This condition involves intentional self-harm resulting from exposure to fibrinolysis-affecting drugs not classified elsewhere, occurring during the initial encounter. Fibrinolysis-affecting drugs modulate the body's ability to dissolve blood clots, and intentional poisoning may involve excessive dosing or deliberate ingestion leading to harmful effects. The term "other" specifies drugs outside the thrombolytic class, such as certain plasminogen activators or fibrinolytic agents.

Causes

Intentional self-harm poisoning may result from deliberate ingestion or administration of fibrinolysis-affecting drugs. This can stem from suicidal intent, medication misuse, or attempts to self-harm. Contributing factors may include access to these medications, underlying mental health conditions, or a desire to manipulate clotting pathways for self-injury.

Risk Factors

• Access to fibrinolysis-affecting drugs (e.g., prescription or over-the-counter).
• History of suicidal ideation or prior self-harm attempts.
• Mental health conditions (e.g., depression, anxiety, or psychosis).
• Substance use disorders involving these medications.
• Social or environmental stressors increasing self-harm risk.

Symptoms

• Excessive bleeding (e.g., bruising, hematomas, gastrointestinal or intracranial hemorrhage).
• Altered clotting function (e.g., prolonged bleeding from minor injuries).
• Signs of systemic toxicity (e.g., hypotension, tachycardia, or organ dysfunction).
• Neurological symptoms (e.g., confusion, dizziness, or loss of consciousness).
• Gastrointestinal distress (e.g., nausea, vomiting, or abdominal pain).

Diagnosis

Diagnosis involves clinical evaluation of symptoms, patient history (including intentional self-harm), and laboratory tests to assess clotting function (e.g., PT, aPTT, fibrinogen levels). Toxicology screening may identify the specific fibrinolysis-affecting drug involved. Imaging (e.g., CT scans) may be used to detect bleeding or organ damage. Documentation of intentional self-harm and the initial encounter context is critical for coding.

Treatment Options

Treatment focuses on stabilizing the patient, controlling bleeding, and addressing the underlying self-harm intent. Interventions may include administering antidotes (if available), blood products (e.g., platelets, cryoprecipitate), or medications to reverse fibrinolysis effects. Psychological support and mental health evaluation are essential. In severe cases, intensive care monitoring or surgical intervention may be required.

Prognosis and Follow-Up

Prognosis depends on the severity of bleeding, timeliness of treatment, and the patient's overall health. Early intervention improves outcomes, but severe hemorrhage or organ damage may lead to long-term complications. Follow-up includes monitoring for recurrent bleeding, assessing mental health needs, and ensuring adherence to safety plans. Regular evaluations by healthcare providers and mental health professionals are recommended.

Complications

• Severe or life-threatening bleeding (e.g., intracranial hemorrhage).
• Organ damage (e.g., kidney failure from hypotension or bleeding).
• Long-term neurological deficits from bleeding events.
• Psychological sequelae (e.g., depression, anxiety, or PTSD).
• Recurrence of self-harm or suicidal behavior.

Lifestyle & Prevention

• Secure storage of fibrinolysis-affecting drugs to limit access.
• Education on medication safety and proper disposal.
• Mental health support and crisis intervention resources.
• Regular screening for suicidal ideation in at-risk individuals.
• Collaboration with healthcare providers to address underlying conditions.

When to Seek Professional Help

Seek immediate medical attention if experiencing uncontrolled bleeding, severe pain, confusion, or loss of consciousness. Contact emergency services or a mental health professional if there are thoughts of self-harm or suicidal intent. Prompt evaluation is critical to prevent life-threatening complications.

Tips for Medical Coders

Document the intentional self-harm context and initial encounter clearly. Code T45.692A is specific to the initial encounter for intentional self-harm by other fibrinolysis-affecting drugs. Ensure documentation supports the intent (e.g., patient statement, clinical assessment) and encounter type (initial vs. subsequent). Verify that the drug class is not classified elsewhere (e.g., thrombolytics) to confirm the "other" designation.